Cell Therapeutics Files For SPA On New Xyotax Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Study will narrow enrollment for Novartis-partnered compound to women with normal estrogen levels, CEO tells "The Pink Sheet" DAILY.
You may also be interested in...
CTI Plans To File Pixantrone For Non-Hodgkin’s Lymphoma In Early 2008
First pixantrone NHL filing likely will be in the “aggressive/salvage setting,” CEO tells “The Pink Sheet” DAILY.
CTI Plans To File Pixantrone For Non-Hodgkin’s Lymphoma In Early 2008
First pixantrone NHL filing likely will be in the “aggressive/salvage setting,” CEO tells “The Pink Sheet” DAILY.
Cell Therapeutics CEO James Bianco: An Interview With “The Pink Sheet” DAILY
Seattle biotech is looking to “build a more integrated portfolio” with offer to purchase Miami-based DOR BioPharma, Bianco says.